Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region


Autoria(s): Kano, Flora S.; Sanchez, Bruno A. M.; Sousa, Tais N.; Tang, Michaelis L.; Saliba, Jessica; Oliveira, Fernando M.; Nogueira, Paulo A.; Goncalves, Alessandra Q.; Fontes, Cor J. F.; Soares, Irene S.; Brito, Cristiana F. A.; Rocha, Roberto S.; Carvalho, Luzia H.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

21/08/2013

21/08/2013

01/08/2012

Resumo

Objective To investigate risk factors associated with the acquisition of antibodies against Plasmodium vivax Duffy binding protein (PvDBP) a leading malaria vaccine candidate in a well-consolidated agricultural settlement of the Brazilian Amazon Region and to determine the sequence diversity of the PvDBP ligand domain (DBPII) within the local malaria parasite population. Methods Demographic, epidemiological and clinical data were collected from 541 volunteers using a structured questionnaire. Malaria parasites were detected by conventional microscopy and PCR, and blood collection was used for antibody assays and molecular characterisation of DBPII. Results The frequency of malaria infection was 7% (6% for P. vivax and 1% for P. falciparum), with malaria cases clustered near mosquito breeding sites. Nearly 50% of settlers had anti-PvDBP IgG antibodies, as detected by enzyme-linked immunosorbent assay (ELISA) with subjects age being the only strong predictor of seropositivity to PvDBP. Unexpectedly, low levels of DBPII diversity were found within the local malaria parasites, suggesting the existence of low gene flow between P. vivax populations, probably due to the relative isolation of the studied settlement. Conclusion The recognition of PvDBP by a significant proportion of the community, associated with low levels of DBPII diversity among local P. vivax, reinforces the variety of malaria transmission patterns in communities from frontier settlements. Such studies should provide baseline information for antimalarial vaccines now in development.

Research Foundation of Minas Gerais State (FAPEMIG)

Research Foundation of Minas Gerais State (FAPEMIG)

Research Foundation of Amazonas State (FAPEAM)

Research Foundation of Amazonas State (FAPEAM)

Brazilian National Research Council (CNPq)

Brazilian National Research Council (CNPq)

Pronex Malaria/CNPq/DECIT/MS

Pronex Malaria/CNPq/DECIT/MS

Identificador

TROPICAL MEDICINE & INTERNATIONAL HEALTH, HOBOKEN, v. 17, n. 8, supl. 1, Part 4, pp. 989-1000, AUG, 2012

1360-2276

http://www.producao.usp.br/handle/BDPI/32640

10.1111/j.1365-3156.2012.03016.x

http://dx.doi.org/10.1111/j.1365-3156.2012.03016.x

Idioma(s)

eng

Publicador

WILEY-BLACKWELL

HOBOKEN

Relação

TROPICAL MEDICINE & INTERNATIONAL HEALTH

Direitos

closedAccess

Copyright WILEY-BLACKWELL

Palavras-Chave #PLASMODIUM VIVAX #DUFFY BINDING PROTEIN #ANTIBODIES #POLYMORPHISMS #FRONTIER SETTLEMENT #P #VIVAX #PROTEINE DE LIAISON DUFFY #ANTICORPS #POLYMORPHISMES #HABITATION FRONTALIERE #P #VIVAX #PROTEINA DE UNION AL DUFFY #ANTICUERPOS #POLIMORFISMOS #EMPLAZAMIENTO FRONTERIZO #NATURALLY ACQUIRED ANTIBODIES #RECEPTOR-BINDING #VACCINE CANDIDATE #BRAZILIAN AMAZON #LIGAND DOMAIN #INHIBITORY ANTIBODIES #RISK-FACTORS #MALARIA #TRANSMISSION #RECOGNITION #PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH #TROPICAL MEDICINE
Tipo

article

original article

publishedVersion